The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Gut and digestion
Does it fix a gut problem?
Inflammatory bowel disease and ulcers have real trials. Most of what gets sold as gut healing does not.
2,413 people · 18 human studies · 17 compounds
- 1,337 people2 studies
Double-blind placebo-controlled phase 3, 1337 adults meeting modified Rome III criteria randomised to plecanatide 3 mg (n equal to 443), 6 mg (n equal to 449) or placebo (n equal to 445). Durable overall complete spontaneous bowel movement responders: 20.1 percent on 3 mg, 20.0 percent on 6 mg, 12.8 percent on...
Therapeutic Advances in Gastroenterology, 2017 · 1,337 people
A phase 3 randomised analysis examining whether age, sex, race and other demographic factors change the treatment response in chronic idiopathic constipation. This is the genuine randomised evidence in this compound's later literature, and it is an analysis of who responds rather than a new efficacy trial.
Clinical and Translational Gastroenterology, 2023 · no headcount in the line
- 184 people1 study1 found nothing
found nothing184 patients on a gluten challenge: 1 mg larazotide limited gluten-induced symptoms and blunted the rise in anti-tTG antibodies, but intestinal permeability (LAMA ratio) did not differ from placebo.
Alimentary Pharmacology and Therapeutics, 2013 · 184 people
- 117 people1 study
Phase 2 RCT in 117 surgical patients (NCT00672074): IV ipamorelin was well tolerated but did not significantly shorten time to first tolerated meal versus placebo (25.3 vs 32.6 h, p=0.15).
International Journal of Colorectal Disease, 2014 · 117 people
- 117 people1 study
Phase 2 randomised controlled trial in 117 surgical patients. Intravenous ipamorelin was well tolerated but did not significantly shorten time to a first tolerated meal against placebo, 25.3 hours versus 32.6 hours, P equal to 0.15. This is the entire published human record for the ipamorelin half of the blend, and it...
International Journal of Colorectal Disease, 2014 · 117 people
- 117 people1 study
117 adults undergoing small and large bowel resection were randomised to intravenous ipamorelin 0.03 mg/kg twice daily or placebo, from postoperative day 1 to day 7 or discharge, with time to tolerating a standardised solid meal as the key efficacy endpoint. This is the only randomised controlled trial of ipamorelin...
International Journal of Colorectal Disease, 2014 · 117 people
- 117 people1 study
117 bowel resection patients randomised to intravenous ipamorelin or placebo twice daily. Safe, and the key efficacy endpoint of time to tolerating a solid meal was the measure it was tested against. This is the only randomised controlled trial of ipamorelin in people.
International Journal of Colorectal Disease, 2014 · 117 people
- 117 people1 study
117 adults after open or laparoscopic bowel resection randomised to intravenous ipamorelin 0.03 mg/kg twice daily or placebo, with time to tolerating a standardised solid meal as the key endpoint. Safety was the main finding. It remains the only randomised controlled trial of ipamorelin in people.
International Journal of Colorectal Disease, 2014 · 117 people
- 95 people1 study1 found nothing
found nothing95 otherwise healthy men with BMI 25.0 to 34.9, three-part partially blinded first-in-human study of single ascending doses from 0.075 to 2.4 mg, with and without liraglutide 0.6 mg. Drug-related adverse events, mainly gastrointestinal, in 39.0% of participants in parts 1 and 2 and 30.6% in part 3. Transient nausea...
Diabetes, Obesity and Metabolism, 2025 · 95 people
- 65 people1 study
Randomised, open-label, placebo-controlled, 65 healthy adults, 14 days. NR and NMN comparably increased circulatory NAD while plain nicotinamide did not do so chronically. Using ex vivo fermentation with human microbiota, the authors found that NR and NMN give rise to nicotinic acid, and that in whole blood ex vivo...
Nature Metabolism, 2026 · 65 people
- 65 people1 study
Phase 2a, 65 adults with type 2 diabetes and overweight or obesity, 49 days of daily cotadutide (50 to 300 mcg) or placebo. Postprandial glucose area under the curve fell 21.5 percent against a 6.3 percent rise on placebo (P below 0.001); weight fell 3.41 percent against 0.08 percent (P equals 0.002); postprandial...
Journal of Clinical Endocrinology and Metabolism, 2020 · 65 people
- 40 people1 study
40 healthy Chinese volunteers, single 2.5 mg dose and weekly titration to 5, 10 and 15 mg. Maximum concentration and area under the curve were linearly proportional to dose across 2.5 to 15 mg, supporting weekly dosing. Body weight change from baseline was minus 3.24, minus 6.26, minus 7.09 and minus 8.30 percent at...
Diabetes, Obesity and Metabolism, 2025 · 40 people
- 39 people1 study
39 adults with functional constipation, four weeks of 12 g chicory inulin daily in a double-blind placebo-controlled crossover. Stool frequency, abdominal symptoms and constipation-related quality of life improved relative to placebo, alongside higher relative abundance of butyrate-producing Anaerostipes and...
BMC Gastroenterology, 2025 · 39 people
- 3 people1 study
Phase 1 over 28 days and phase 2 over 12 weeks, both randomised, double-blind and placebo-controlled. Phase 1 produced dose-dependent weight loss with statistically significant reductions against placebo at all doses, plus reduced appetite and delayed gastric emptying. Phase 2 produced significantly greater mean...
Obesity, 2026 · 3 people
- no headcount stated1 study
Randomized double-blind placebo-controlled crossover in healthy obese subjects with a mean BMI of 39. Five days of native GLP-1 given before meals cut mean food intake per meal 15% and produced 0.55 kg of weight loss, with slowed gastric emptying as the probable mechanism. The native hormone does what its analogues...
British Journal of Nutrition, 2004 · no headcount in the line
- no headcount stated1 study
PEGASUS. Phase 3, open-label, randomised, in adults with paroxysmal nocturnal haemoglobinuria and haemoglobin below 10.5 g/dL despite eculizumab. 41 to pegcetacoplan monotherapy, 39 to eculizumab. Primary endpoint, change in haemoglobin at week 16, favoured pegcetacoplan by an adjusted least-squares mean difference of...
New England Journal of Medicine, 2021 · no headcount in the line
- no headcount stated1 study
STEP 1. Mean body weight changed by 14.9% with semaglutide 2.4 mg weekly against 2.4% with placebo at week 68, an estimated treatment difference of 12.4 percentage points. 50.5% of the semaglutide group lost 15% or more of body weight against 4.9% on placebo. Nausea and diarrhoea were the most common adverse events,...
New England Journal of Medicine, 2021 · no headcount in the line
- no headcount stated1 study
ENLIVEN phase 2b, 222 randomised and 219 treated, biopsy-confirmed NASH with F2 or F3 fibrosis, 24 weeks. Fibrosis improvement without NASH worsening: 7 percent placebo, 22 percent on 15 mg weekly, 26 percent on 30 mg weekly (p 0.009), 27 percent on 44 mg every 2 weeks (p 0.008). NASH resolution: 2 percent placebo...
New England Journal of Medicine, 2023 · no headcount in the line
- no headcount stated0 studies
Nanoparticle-delivered KPV accelerated mucosal healing and lowered TNF-alpha in a mouse colitis model.
Molecular Therapy, 2017 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.